Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies--response.

Arjaans M, Oosting SF, Schröder CP, de Vries EG.

Cancer Res. 2013 Dec 1;73(23):7147-8. doi: 10.1158/0008-5472.CAN-13-2532. Epub 2013 Nov 21. No abstract available.

2.

Benefits of vascular normalization are dose and time dependent--letter.

Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK.

Cancer Res. 2013 Dec 1;73(23):7144-6. doi: 10.1158/0008-5472.CAN-13-1989. Epub 2013 Nov 21. No abstract available.

3.

Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schröder CP, de Vries EG.

Cancer Res. 2013 Jun 1;73(11):3347-55. doi: 10.1158/0008-5472.CAN-12-3518. Epub 2013 Apr 11.

4.

Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.

Hurwitz SJ, Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Rycroft D, Pan L, Tighiouart M, Shin HJ, Koenig L, Wang Y, Chen ZG, Shin DM.

Cancer Chemother Pharmacol. 2012 Mar;69(3):577-90. doi: 10.1007/s00280-011-1713-x. Epub 2011 Sep 13.

PMID:
21913035
5.

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN.

J Nucl Med. 2007 Aug;48(8):1313-9. Epub 2007 Jul 13.

6.

Breaking down the evidence for bevacizumab in ovarian cancer.

Shu CA, Konner JA.

Oncologist. 2015 Feb;20(2):91-3. doi: 10.1634/theoncologist.2014-0302. Epub 2015 Jan 19. No abstract available.

7.

Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.

Martinez-Poveda B, Gomez V, Alcaide-German M, Perruca S, Vazquez S, Alba LE, Casanovas O, Garcia-Bermejo ML, Peso L, Jimenez B.

Int J Oncol. 2011 Sep;39(3):543-52. doi: 10.3892/ijo.2011.1074. Epub 2011 Jun 9.

PMID:
21667025
8.

Bevacizumab in ovarian cancer.

Mountzios G, Pentheroudakis G.

N Engl J Med. 2012 Mar 29;366(13):1257; author reply 1258. doi: 10.1056/NEJMc1201044#SA3. No abstract available.

PMID:
22455430
9.

Bevacizumab in ovarian cancer.

Copur MS, Obermiller AM, Ramaekers R.

N Engl J Med. 2012 Mar 29;366(13):1256-7; author reply 1257-8. doi: 10.1056/NEJMc1201044#SA2. No abstract available.

PMID:
22455429
10.

Bevacizumab in ovarian cancer.

Korn EL, Freidlin B, Abrams JS.

N Engl J Med. 2012 Mar 29;366(13):1256; author reply 1257-8. doi: 10.1056/NEJMc1201044#SA1. No abstract available.

PMID:
22455428
11.

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.

Clin Cancer Res. 2008 Dec 1;14(23):7781-9. doi: 10.1158/1078-0432.CCR-08-0243.

12.

Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

Kaye SB.

J Clin Oncol. 2007 Nov 20;25(33):5150-2. No abstract available.

PMID:
18024860
13.

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.

Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD.

J Exp Clin Cancer Res. 2011 Nov 10;30:106. doi: 10.1186/1756-9966-30-106.

14.

Personalized ovarian cancer treatment.

Rodriguez AO.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):1-2. doi: 10.1097/GCO.0b013e32834fb0a8. No abstract available.

PMID:
22193244
15.

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.

Abbas N, Bruland ØS, Brevik EM, Dahle J.

Nucl Med Commun. 2012 Aug;33(8):838-47. doi: 10.1097/MNM.0b013e328354df7c.

PMID:
22643311
16.

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Simpkins F, Belinson JL, Rose PG.

Gynecol Oncol. 2007 Oct;107(1):118-23. Epub 2007 Jul 23.

PMID:
17658587
17.

Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland.

Collins IM, King F, O'Byrne K.

Ir J Med Sci. 2012 Sep;181(3):451-2. doi: 10.1007/s11845-011-0772-7. Epub 2011 Oct 20. No abstract available.

PMID:
22012551
18.

Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.

Liotta M, Rose PG, Escobar PF.

Gynecol Oncol. 2009 Nov;115(2):308-9. doi: 10.1016/j.ygyno.2009.08.003. Epub 2009 Sep 8. No abstract available.

PMID:
19740533
19.

Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer.

Sánchez-Muñoz A, Jurado JM, Pérez-Ruiz E, Alba E.

Clin Transl Oncol. 2009 May;11(5):329-31.

PMID:
19451068
20.

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.

Weisshardt P, Trarbach T, Dürig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergün S, Klein D.

Histochem Cell Biol. 2012 Mar;137(3):391-401. doi: 10.1007/s00418-011-0898-8. Epub 2011 Dec 23.

PMID:
22193946

Supplemental Content

Support Center